Medpace Holdings, Inc. $MEDP Shares Sold by Truist Financial Corp

Truist Financial Corp lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,817 shares of the company’s stock after selling 2,708 shares during the quarter. Truist Financial Corp’s holdings in Medpace were worth $6,637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Baillie Gifford & Co. boosted its stake in shares of Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of Medpace by 32.8% during the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock worth $184,715,000 after acquiring an additional 81,250 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms announced or reiterated class-action lawsuits against Medpace, alleging investor harm and potential violations of federal securities laws. Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: One update specifically tied the litigation to a sharp prior stock drop and claims that Medpace may have concealed backlog deterioration and other issues, which can weigh on investor sentiment. MEDP Investor News: Medpace Stock Drops 16% Amid Cancellation Rates Triggering Securities Fraud Class Action – Contact BFA Law if You Suffered Losses
• Negative Sentiment: The repeated deadline reminders from several firms may keep attention on legal risks and uncertainty rather than fundamentals in the near term. MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit

Medpace Stock Performance

MEDP stock opened at $424.00 on Friday. Medpace Holdings, Inc. has a 1 year low of $284.48 and a 1 year high of $628.92. The stock’s 50 day moving average price is $467.80 and its 200 day moving average price is $531.00. The firm has a market cap of $12.11 billion, a P/E ratio of 26.65, a PEG ratio of 2.15 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MEDP shares. Barclays decreased their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Leerink Partners decreased their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Robert W. Baird decreased their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $467.08.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.